Furthermore, it was also observed that as the clinical stages progressed in patients with COAD, COADREAD, ESCA, KIPAN, KIRC, THCA, and OV, there was a decreasing trend in KLF3 expression, except for PAAD patients where the opposite trend was observed (Figure 3B, all p<0.05). Here, KLF3 is linked to pancreatic adenocarcinoma.